Skip to main content
Equibles
ONCY logo

ONCY · Oncolytics Biotech Inc

Track ONCY — free

Use ONCY with AI

Ask our own analyst here, or connect this data to the AI you already use.

Ask ALVIS about ONCY

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

or use your own AI

The free Equibles MCP server lets any client query SEC filings, earnings calls, KPIs, holdings and prices directly — read-only, OAuth-secured, cited to the filing.

ChatGPT Claude Gemini
Server URL
https://mcp.equibles.com/mcp
All connection guides →
$0.84 +0.04 (+5.16%) At close · Aug 21
Going-concern doubt — flagged Aug 12, 2026

Substantial doubt about the company's ability to continue as a going concern.

“Based on our current operating plan, we expect that our existing cash resources, even when considered together with capital that may be raised under our equity distribution arrangements, are sufficient to fund near‑term operating milestones but are not sufficient to fund our planned operations for at least twelve months from the date of issuance of our condensed consolidated financial statements included in this quarterly report. These conditions raise substantial doubt about our ability to continue as a going concern.”
View the 10-Q filed Aug 12, 2026
Market Cap
$107.50M
Shares
127.51M

Price & Indicators

Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$0.84 Open$0.80 Day$0.80–0.85 52W close$0.75–1.42 Avg vol 30d1.2M Short int8.2M · 6.5% float · 7.1d Short vol54% Last earningsMar 31, 2025 DataJan 2020–Aug 2026 Filing10-Q · Aug 12

Up next

FQ3-26 quarter ends
~Sep 30, 2026 Est
Latest filing: 10-Q
filed Aug 12, 2026

Equibles Rating

blended score · not investment advice
Overall
Sell
SellHoldBuy
Technical Neutral Momentum Weak Sentiment Neutral Fundamentals Fair Quant / Vol Very High
Market backdrop VIX 15.1 · calm Equity put/call 0.51
Technical
price trend
Neutral
50 / 200-day cross No cross
Price vs 200-day avg −11%
below
Price vs 50-day avg −1%
below
RSI (14) 53
neutral
MACD trend Positive
52-week position 14%
near low
Volume (OBV) Confirms
volume backs price
Momentum
relative strength
Weak
1-month return +4%
trailing
6-month return −17%
trailing
YTD return −3%
this year
Relative strength −29%
vs S&P · 6-mo
Sentiment
smart money
Neutral
Trend (MA cross) No cross
50d $1 › 200d $1 — 200d above 50d
Institutional flow Accumulating
+25% holders QoQ · +27 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Rising
6.45% of float · ▲ +3.5% MoM · 7.1 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
74 holders — near 3-yr high, broad support
Squeeze score 66
elevated · 0–100
Fundamentals
Fair
EPS growth 0%
Y/Y
Free cash flow $-20.1M
Balance sheet $5.2M
net cash
Quant / Vol
risk profile
Very High
Volatility 83%
annualized · 1-yr
Max drawdown −47%
past year
ATR 5.5%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Neutral
2 · 4 · 1
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
−11% Bearish
Price vs 50-day avg
−1% Neutral
RSI (14)
53 Neutral
MACD trend
Positive Bullish
52-week position
14% Bearish
Volume (OBV)
Confirms Neutral
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross) No cross
50d $1 › 200d $1 — 200d above 50d
Institutional flow Accumulating
+25% holders QoQ · +27 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Rising
6.45% of float · ▲ +3.5% MoM · 7.1 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
74 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $1 Now $1 · 14% Range high $1
vs 200-day avg -11% vs 50-day avg -1%

Illustrative technical + ownership context — a signal mix, not investment advice.

Versus peers

Biotechnology — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
ONCY
Oncolytics Biotech Inc
this stock
$107.50M -3.1% — — 6.5%
VRTX
Vertex Pharmaceuticals Inc / Ma
 $138.91B +20.9% +46.2% 31.9 1.6%
REGN
Regeneron Pharmaceuticals, Inc.
 $85.87B +8.1% +20.8% 20.7 3.3%
ARGX
Argenx SE
 $64.66B +23.6% — — 2.1%
CSLLY
Csl Ltd
 $57.97B — — — 0.0%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Accumulating
Holders
74
% held
3.1%
Net QoQ
+81.9K sh
Top holder
MARSHALL WACE, LLP
Held Float
View
Held by Funds
Fund positions
1
View
Short & Settlement
Short Interest Rising
Shares short
8.2M
Days to cover
7.1d
Change
+279.8K sh
View
Short Volume
Short vol %
54%
As of
Aug 21, 2026
Short Total
View
Fails to Deliver
FTD shares
23.9K
Value
$17.9K
As of
Jul 31, 2026
View
Off-Exchange
Off-exchange %
65.2%
Week of
Jul 13, 2026
Off-exch Lit
View
Financials
Financials
Net income (FY)
$-28.8M
EPS diluted
$-0.30
View
Filings
SEC Filings
Latest
8-K
Filed
Aug 18, 2026
This year
26
View
Earnings & Events
Earnings Calls
Last call
Mar 31, 2025
View

Performance

5D 20D 120D MTD YTD
ONCY +1.1% +4.1% -17.3% +11.9% -3.1%
SPY -1.4% +3.6% +11.6% +2.5% +12.3%
vs SPY +2.5% +0.5% -28.9% +9.4% -15.4%
Key facts CIK 1129928 CUSIP 68237V103 13F (30d) 62 filings 62 filers Visit website Investor relations

Report a Problem

Category
Description
Email (optional, for follow-up)